Abstract
The factors affecting gut activity in inflammatory bowel disease are unclear, but purines and kynurenines may be involved in the regulation of neuronal activity and therefore gut motility and secretion. We have measured the serum levels of these compounds in patients and in sex-and age-matched controls. Purines and kynurenines were analysed using HPLC. The levels of tryptophan and its metabolites 3hydroxykynurenine, 3-hydroxyanthranilic acid and xanthurenic acid were unchanged in all patients. However, the levels of kynurenine and kynurenic acid were significantly elevated in patients with inflammatory bowel disease when compared to control subjects. There were no significant differences between patients and controls for any of the purines analysed or for neopterin. In the inflammatory bowel disease patients serum lipid peroxidation products were significantly elevated when compared to control subjects, suggesting the presence of increased oxidative stress consistent with inflammatory activity. The elevated level of kynurenic acid may represent either a compensatory response to elevated activation of enteric neurones, or a primary abnormality, which induces a compensatory increase in gut activity, but may indicate a role for kynurenine modulation of glutamate receptors in the symptoms of inflammatory bowel disease.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
T.W. Stone, H.A. Simmonds, Purines: Basic and Clinical Aspects (Kluwer Press, Dordrecht, 1991).
I.M. Coupar, D.L. Hancock, The adenosine agonist NECA inhibits intestinal secretion and peristalsis, J. Pharm. Pharmac. 46, 801–804 (1994).
V.H. Hopker, M.J. Saf rey, G. Bumstock, Neurite outgrowth of striatal neurons in vitro: Involvement of purines in the growth-promoting effect of myenteric plexus explants, Intern. J. Develop . Neurosci. 14, 439–451 (1996).
F.L. Christoti, H. Zhang, J.G. Yu, J. Guzman, J. Xue, M. Kim, Y.Z. Wang, H.J. Cooke, Differential gene expression of adenosine Al, Ala, Alb, and A3 receptors in the human enteric nervous system, J. Comp. Neurol. 439, 46–64 (2001).
T.W. Stone, The neuropharmacology of quinolinic and kynurenic acids, Pharmacol. Revs. 45, 309–379 (1993).
T.W. Stone, The development and therapeutic potential of kynurenic acid and kynurenine derivatives for CNS protection, Trends Pharmacol. Sci. 21, 149–154 (2000).
T.W. Stone, Kynurenines in the CNS - from endogenous obscurity to therapeutic importance, Progr. Neurobiol. 64, 185–218 (2001).
T.W. Stone, M.N. Perkins, Quinolinic acid: a potent endogenous excitant at NMDA receptors, Europ. J. Pharmacol. 72, 411–412 (1981).
M.N. Perkins, T.W. Stone, An iontophoretic investigation of the action of convulsant kynurenines and their interaction with the endogenous excitant kynurenic acid, Brain Res. 247, 184–187 (1982).
S.S. Gill, R.W. Mueller, P.F. McGuire, Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity, Toxicologic Pathol. 28, 277–284 (2000).
T.M. Skerry, PG. Genever, Glutamate signalling in non-neuronal tissues, Trends Pharmacol. Sci. 22 174–181 (2001).
H.E. Shannon, B.D. Sawyer, Glutamate receptors of the NMDA subtype in myenteric plexus of the guinea pig ileum, J. Pharmacol. Exp. Therap. 215, 518–523 (1989).
S. Luzzi, S. Zilletti, S. Franchi-Micheli, A.M. Gori, F. Moroni, Agonists, antagonists and modulators of excitatory amino acid receptors in the guinea-pig myenteric plexus, Brit. J. Pharmacol. 95,1271–1277 (1988).
D. Fuchs, G. Weiss, G. Reibnegger, H. Wachter, The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases, Crit. Rev. Clin. Lab. Sci,29,307–341 (1992).
G. Judmaier, P. Meyersbach, G. Weiss, H. Wachter, G. Reibnegger, The role of neopterin in assessing disease activity in Crohn’s disease: classification and regression trees, Amer. J. Grutroentero/. 88, 706–71 I (1993).
D. Neiderwieser, D. Fuchs, A. Hausen, G..ludmaier, G. Reibnegger, H. Wachter, C. Huber, Neopterin as a new biochemical marker in the clinical assessment of ulcerative colitis, Imntunobiol. 170,320–326 (1985).
B. Duclos, J.M. Reimund, J.M. Lang, G. Coumaros, P. Chamouard, L. Lehr, R. Baumann, C. Koehl, J.P. Weill, Mononuclear cell activation in Crohn’s disease. Evaluation using serum assay of neopterin and interleukin-2 soluble receptors, Gastroenterol. Gin. Biol. 14,22–27 (1990).
R.S. Walmsley, R.C.S. Ayres, R.E. Pounder, R.N. Allan, A simple clinical colitis activity index, Gut 43. 2x)32 (1998).
R.F. Harvey, J.M. Bradshaw, A simple index of Crohn’s disease activity, Lancet I, 514 (1980).
D.A. Drossman, An integrated approach to the irritable bowel syndrome, Aliment. Phnrrnncol. Iherap. 13 (sappl 2), 3–14 (1999).
N.C. Danbolt, Glutamate uptake, Progr . Neurobiol . 65, 1–105 (2001).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Forrest, C.M., Gould, S.R., Darlington, L.G., Stone, T.W. (2003). Levels of Purine, Kynurenine and Lipid Peroxidation Products in Patients with Inflammatory Bowel Disease. In: Allegri, G., Costa, C.V.L., Ragazzi, E., Steinhart, H., Varesio, L. (eds) Developments in Tryptophan and Serotonin Metabolism. Advances in Experimental Medicine and Biology, vol 527. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0135-0_46
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0135-0_46
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4939-6
Online ISBN: 978-1-4615-0135-0
eBook Packages: Springer Book Archive